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Summary  
Congenital erythrocytosis is by definition present from birth. Patients frequently present in 
childhood or as young adults and a family history may be present. The erythrocytosis can be primary 
where there is an intrinsic defect in the erythroid compartment or secondary where increased 
erythropoietin production from some source leads to an erythrocytosis. Primary causes include 
erythropoietin receptor mutations. Congenital secondary causes include mutations in the genes 
involved in the oxygen sensing pathway and haemoglobins with abnormal oxygen affinity and very 
rare causes such as bisphosphoglycerate mutase deficiency and hereditary ATP increase. Having 
established that a congenital erythrocytosis is a likely diagnosis, molecular investigations should be 
carried out looking for described molecular abnormalities. A congenital erythrocytosis may be an 
incidental finding but non-specific symptoms are described. Major thromboembolic events have 
been noted in some cases. Pulmonary hypertension has also been reported in some cases.  Low dose 
aspirin and venesection are therapeutic manoeuvres which should be considered in managing these 
patients. In those with Chuvash polycythaemia with VHL mutations JAK inhibition may prove to be a 
useful therapeutic option. 
Keywords: Congenital erythrocytosis, erythropoietin, erythropoietin receptor, oxygen sensing 
pathway, high affinity haemoglobin. 
Introduction 
An erythrocytosis is present when the red cell mass is greater than 125% of predicted for sex and 
body mass. This usually correlates with an elevated Haemoglobin (HB) and/or Haematocrit (Hct) 
although not always As the work of Johansson and colleagues demonstrates it is possible to have a 
raised red cell mass with a normal Hb or Hct [1]. However, an Hct above 0.60 in a male and 0.56 in a 
female always reflects an increased red cell mass. A congenital erythrocytosis by definition is present 
from birth and is therefore thought to be due to a germline defect. It can be and is usually detected 
when a blood check is carried out in a young child or in early adult lifebut ,as awareness of these 
defects grows testing is more widespread and thus it may be much later before it is detected.  
An erythrocytosis congenital or otherwise is classified as primary where there is an intrinsic defect in 
the bone marrow precursors driving the red cell production. In primary erythrocytosis the 
erythropoietin (EPO) level is reduced below normal commensurate with a primary erythroid defect. 
In contrast in a secondary erythrocytosis a factor extrinsic to the bone marrow is driving the red cell 
production. This is usually EPO from some source. Therefore in a secondary erythrocytosis the EPO 
levels are either elevated or normal (which is inappropriate for a raised HB and therefore reflects the 
increased EPO drive to erythropoiesis). With congenital erythrocytosis, germline defects have been 
identified in some cases which result in either a primary  or secondary defect where the molecular 
lesion results in increased EPO production. 
The known causes of a congenital erythrocytosis are listed in Table 1 and will be discussed. 
 
 
Primary Congenital Erythrocytosis 
Erythropoietin Receptor 
A cytokine links with its receptor on the cell surface. Once this occurs then a number of downstream 
processes take place leading to cell signalling and cell production. EPO is one such cytokine which 
links on the cell surface to the erythropoietin receptor (EpoR). When this happens, the proteins JAK2 
and STAT5 autophosphorylate, STAT5 dimerises, translocates to the nucleus, and then triggers 
downstream signalling and production of red cells.  The process is then turned off when a further 
protein SHP-1 attaches to its docking site and down-modulates the receptor. However, mutations 
occur in the gene for the EpoR which lead to premature stop codons and a truncated receptor. The 
truncated receptor looses the SHP-1 docking site and thus once EPO attaches to the receptor it is 
switched on but does not get switched off again and therefore continues to drive red cell production 
without further EPO stimulation (Figure 1).The first such EpoR mutation was described in an Olympic 
medal winning cross country skier who was part of a large family where many members had 
erythrocytosis [2] At least 11 mutations in the EpoR have been described which lead to a truncated 
receptor and erythrocytosis [3] and therefore EpoR mutations are infrequently found as a cause of 
primary congenital erythrocytosis usually in young adults. 
LNK mutations 
The lymphocyte adaptor protein (LNK) is involved in cell signalling and is a negative regulator of the 
cytokine signalling by attenuating JAK activation. This includes the EPO signalling pathway and it is 
shown that Lnk via the SH2 domain negatively regulates EpoR signalling by attenuating Jak2 
activation and thus EPO mediated erythropoiesis [4] Mutations have been described in LNK in 
myeloproliferative neoplasms. These mutations result in a defective LNK protein which does not act 
as a negative regulator  of the JAK/ STAT pathway downstream of the cytokine attachment to it’s 
receptor and thus lead to increases downstream erythropoiesis and  a primary erythrocytosis (with 
an associated low EPO level) [5]. In several cases the mutation was shown to be in the germline [6]. 
LNK mutations have also been described in a small number of reports of idiopathic erythrocytosis 
and it is postulated that this may be a possible explanation for idiopathic erythrocytosis in some 
instances [7]. In these cases the germline status has mainly not been investigated. However as 
germline mutations have been described in myeloproliferative neoplasms there is a least the 
possibility that a germline LNK mutations could be found accounting for congenital erythrocytosis.  
Secondary Congenital Erythrocytosis 
The oxygen sensing pathway 
The human organism has a sensitive mechanism for sensing oxygen and responding to hypoxia. This 
involves a number of proteins. This system consists of the prolyl hydroxylases (PHDs) which have 
three isoforms PHD1, PHD2 and PHD3. In normoxia, the PHDs hydroxylate hypoxia-inducible factor 
(HIF) which consists of both an alpha and a beta subunit. When hydroxylation occurs, the von-
Hippel-Lindau tumour suppressor protein (VHL) is bound. This is a substrate recognition unit of the 
E3 ubiquitin ligase complex. Ubiquitination and degradation of HIF then occurs in the proteasome 
and thus low HIF levels are maintained in normoxia. In contrast with hypoxia, less hydroxylation 
occurs, HIF escapes VHL mediated degradation. Levels of HIF alpha then rise and it dimerises with 
the beta subunit. The combined HIF protein translocates to the nucleus and binds to the hypoxia 
response element in the 3’ region of the target genes. This then leads to HIF regulated transcription 
and production of a number of proteins including those involved in glycolysis, glucose uptake, 
angiogenesis and EPO (Figure 2) [8]. 
 
Mutations of the oxygen sensing pathway  
PHD2 
A first in man mutation in the PHD2 (EGLN1) gene was discovered in a family with erythrocytosis, a 
heterozygous change C950G leading to a protein alteration of proline to arginine at codon 317 
[9].Two affected siblings all had mild erythrocytosis with normal or increased EPO levels while an 
unaffected had normal haematology and did not have the mutation. Of interest the other parent 
who was deceased had been treated for polycythaemia for some years and the mutation was 
detected in tissue from this individual.  In vitro studies showed that the mutation had abnormal 
activity with decreased HIF binding and decreased HIF inhibitory activity supporting that the 
mutation would lead to erythrocytosis. A mouse model of the mutation provided further evidence 
that this mutation as a cause of erythrocytosis [10].  A number of further mutations in PHD2 have 
now been documented in individuals with congenital erythrocytosis [11]. One of these has been 
identified in a nearby codon in PHD2, resulting in an A1121G change and a His374Arg amino acid 
substitution. This individual, thirteen years after presentation, was found to have a paraganglioma. 
The mutation was also found in the tumour tissue absence of the wild type PHD2 allele thus loss of 
heterozygosity. This suggests in this case that PHD2 was acting as a tumour suppressor gene. Of 
note, paragangliomas are vascular tumours and up-regulation of the HIF pathway may contribute to 
tumour growth. 
Thus PHD2 mutations are clearly an explanation in some cases for a secondary congenital 
erythrocytosis. To date no mutations have been discovered in the other PHD genes 
VHL  
The first defects in the oxygen sensing pathway were discovered in the VHL gene. A homozygous 
mutation in the VHL gene C598T was identified in a large cohort of individuals with erythrocytosis in 
the remote upper Volga region of Russia, Chuvashia [13]. In this remote area with a population of 
just over one million, erythrocytosis was known to be endemic. Over a hundred individuals from 
more than 80 families had Hbs usually over 200g/L, normal or elevated EPO levels and inheritance 
was autosomal recessive. Investigation lead to the VHL gene as the candidate gene and sequencing 
identified the homozygous mutation. The mutant protein was shown to have  had reduced activity 
as a negative regulator of HIF-1 dependent gene transcription and result in increased expression of 
HIF-1 regulated genes target genes including EPO [13]. VHL protein is a tumour suppressor but there 
is no increase in malignancy found in those with Chuvash polycythaemia. This homozygous mutation 
in the VHL gene has been identified in other patients with congenital erythrocytosis from other areas 
of the world. A number of sporadic cases have been identified in the UK and Ireland but many of 
these were of Pakistani or Bangladeshi origin [14]. A large cohort, actually with a higher gene 
frequency that in Chuvashia, have been identified in the Italian island of Ischia [15]. Many of these 
groups have been looked at further and a common founder has been potentially identified [16]. A 
few compound heterozygotes of the VHL gene with erythrocytosis have also been seen [11]. There 
are also a few cases where there is only a heterozygote change with the other VHL allele normal and 
intact. It is not clear in these cases how erythrocytosis results but another undiscovered lesion has to 
be postulated [17]. 
 HIF2A 
 The first mutation in HIF2A (EPAS1) was a gain-of –function mutation which was identified in 3 
generations of a family associated with erythrocytosis. The propositus presented at the age of 23 
years. His mother and grandmother were also known to have erythrocytosis and they were found to 
carry the same mutation whereas unaffected family members did not have the mutation. These 
individuals had a G1609T change leading to a change at codon 537 from glycine to tryptophan. Gly 
537 is an amino acid which is highly conserved across species in all HIF-2α proteins. It is also near to 
the residue Pro531 which is the primary hydroxylation site in HIF-2α and is not present in the other 
HIF-1α and HIF-3α proteins. Therefore this residue is likely to be of importance. In vitro studies 
showed that the altered protein binds PHD2 and VHL differently that wild type protein, is degraded 
more slowly, and induces downstream genes supporting a mutant protein which has a gain-of -
function [18]. Other gain-of-function mutations in HIF2A associated with congenital erythrocytosis 
have been identified in other kindred. These result in amino acid changes in the same or nearby 
residues [19, 20]. 
 Another family with 4 generations who had erythrocytosis, was found to have the Gly537Arg 
mutation. In this kindred 2 affected individuals had pulmonary hypertension in their sixth decade 
with no evidence of thromboembolism. Expression of mutants in a cell line showed that there was 
increased activity with the Gly537Arg mutant compared to wild type and that the Gly 537Arg mutant 
was more active than the original Gly 537Trp mutant which may be consistent with the severe 
phenotype in these kindred [21].   
 
BPGM  
In the red cell, 2,3 bisphosphoglycerate (2,3-BPG) binds to the haemoglobin and converts the 
haemoglobin molecule to a low oxygen affinity state shifting the oxygen affinity curve to the right. 
Deficiency of 2,3-BPG moves the oxygen affinity curve to the left and the haemoglobin is kept in a 
high oxygen affinity state. With a state of high oxygen affinity of haemoglobin oxygen is not 
delivered to tissues and a compensatory erythrocytosis results. In the glycolytic pathway, the 
production of 2,3-BPG involves the conversion of 1,3 BPG to 2,3 BPG which is catalysed by 
bisphosphoglycerate mutase (BPGM). Mutations in the BPGM gene lead to an abnormal functioning 
BPGM and deficiency of 2,3-BPG, thus shifting the oxygen affinity curve to the left and congenital 
erythrocytosis [22]. Autosomal dominant and recessive cases have been described. These mutations 
are extremely rare and assays for BPMG and 2,3 BPG are now very difficult to get carried out. 
Recently a Caucasian who had presented with erythrocytosis at the age of 27 years and had been 
extensively investigated for other oxygen sensing pathway mutations had a  novel missense 
mutation in the BPGM gene with a G268A substitution resulting in the substitution of arginine with 
histidine at residue 90 (R90H) was identified by whole-genome sequencing [23]. As this technology 
comes into widespread use it is likely that other such mutations may be discovered. 
High oxygen affinity haemoglobins 
Oxygen is transported to the tissues bound to haemoglobin in the blood. The oxygenation and 
deoxygenation of haemoglobin occurs at the heme iron binding site and the affinity for oxygen 
depends on the haemoglobin. This is expressed by the shape of the haemoglobin-oxygen 
dissociation curve. An high oxygen affinity haemoglobin, has a left shifted haemoglobin oxygen 
dissociation curve, oxygen is tightly bound, and not easily released to the tissues. At tissue level this 
results in a relative, hypoxia, EPO production and as a result secondary erythrocytosis. 
The first reported high oxygen affinity haemoglobin was Haemoglobin Chesapeake and 
approximately 100 high oxygen affinity variants have been described both α and β globin gene 
mutations resulting in stable and unstable haemoglobins. These have an autosomal dominant 
inheritance and therefore there is often a family history to be elicited. Individuals often present with 
erythrocytosis and investigation for a high affinity Hb should be considered24].A p50 calculation 
should be carried out. This can be done on routine blood gas analysers. Sequencing of the globin 
genes will identify and mutations and with the widespread use of molecular testing this may be the 
easiest way to look for these defects. 
Methaemoglobinaemia 
Normally 1% of haemoglobin is in the methaemaehoglobin form. Methemoglobin impairs oxygen 
binding and transport and if a large amount of haemoglobin is in the methemoglobin form then 
cyanosis results and a compensatory erythrocytosis develops. Congenital methemoglobinaemia can 
arise either because of a deficiency cytochrome b5 reductase or an abnormal M Haemoglobin. 
Abnormal M haemoglobins are inherited in an autosomal dominant manner and α,β,and γ globin 
variants have been reported[25]. In an α chain variant cyanosis will be present from birth while with 
a β chain variant cyanosis will not appear until 3 months postpartum as the changeover from fetal to 
adult haemoglobin occurs. This observation may help in diagnosing the cause of the cyanosis. NADH-
cytochrome b5 reductase also leads to methaemoglobinaemia. NADH-cytochrome b5reductase   
catalyzes electron transfer from NADH to cytochrome b5 and is encoded by the CYB5R3 gene.  Over 
40 mutations of this gene have been described and inheritance is autosomal recessive. Type 1 
mutations lead to a defect in the erythrocytes only whereas type 11 mutations have accompanying 
neurological defects [26] 
 
Inherited increased ATP 
Erythrocytosis has been reported in families who have been described with increased ATP levels 
associated with low 2.3-BPG levels with autosomal dominant inheritance. Elevated pyruvate kinase 
activity has been associated but the relationship is not fully explained [27]. These extremely rare 
described defects should perhaps be considered as causes of congenital erythrocytosis. 
Investigation 
Investigation of a congenital erythrocytosis starts with careful history and examination. In the history 
features which could indicate a congenital cause include an early age of onset and a family history. It 
is necessary to explore for other causes of erythrocytosis in the history and on examination in order 
to eliminate other reasons. Laboratory investigation commences with a repeat blood count for 
confirmation. Next an EPO level will indicate, depending on the result, whether the erythrocytosis is 
primary or secondary. If it is not clear that there is a true erythrocytosis a red cell mass study should 
be carried out to confirm that the red cell mass is greater than 125% of predicted. A P50 test can be 
carried out to examine oxygen affinity in the patient if available. Haemoglobin electrophoresis may 
also be useful to look for abnormal haemoglobins although if may be preferred to look directly at the 
globin genes for mutations. Molecular analysis can there be carried out with sequencing of individual 
genes where mutations have been described (Table 2). This requires a considerable amount of 
laboratory time effort. It is probable that in the future this will be done in more comprehensive next 
generation sequencing panels. 
Clinical consequences 
The clinical effects of congenital erythrocytosis are very variable. In many patients the erythrocytosis 
is an incidental finding. However, they may come to clinical attention because of vague symptoms 
which may be associated with hyperviscosity. Symptoms such as weakness, fatigue, headache, 
blurred vision and slow mentation may be described. On examination a plethoric appearance may 
be noted.  
Complications are those associated with hyperviscosity and the main events described are 
thromboembolic events. In the Chuvash cohort with the homozygous VHL mutation retrospectively, 
life expectancy was reduced compared to controls and causes of death were thromboembolic [28]. 
All there cases are very rare and there is no clear pattern of events. However, there are reports of 
serious, life threatening and unusual thromboembolic events occurring in young individuals with 
oxygen sensing pathway mutations [17]. There are now also reports that pulmonary hypertension 
may occur in some of these cases and it is necessary to consider screening for this complication [21]. 
Management 
Congenital erythrocytosis is very rare and there is little evidence to guide management. There are 
some options which should be considered. Low dose aspirin has been shown to be of use for 
prophylaxis of thromboembolic events in the acquired disorder polycythaemia and there is rationale 
to consider this in congenital erythrocytosis in those who do not have a contraindication to aspirin. It 
should be noted however, that in retrospective studies, there was no relationship between aspirin 
use and outcome in Chuvash polycythaemia [28]. 
Venesection will reduce the Hct and blood viscosity and potentially could reduce the risk of 
thromboembolic events. It is of note that the relationship between reduction of the Hct and 
thromboembolic events in the Chuvash cohort was not conclusive. In should also be noted that in 
some at least of the oxygen sensing mutations the effect of the mutation is an abnormal physiology 
and the raised Hct may be required for functioning with the defect [29]. The other physiological 
issue which must be considered is that in those the erythrocytosis results from a left shifted oxygen 
dissociation curve, oxygen delivery to the tissues is reduced and there is relative tissue hypoxia so 
the raised Hct may be required to deliver enough oxygen to the tissues. 
 It may also be very difficult to reduce the Hct by venesection by a meaningful amount particularly in 
those with very high Hcts. Nevertheless it may be reasonable to consider venesection to reduce the 
Hct particularly in those with symptoms (dizziness, dyspnoea and others). Response to venesection 
should then be assessed. 
It has recently been shown in mice that the Chuvash VHL mutants have an altered affinity for the 
cytokine signalling-1 (SOCS1) and do not degrade JAK2 [30]. As JAK inhibitors are now available in 
clinical practice they have been tried with some shown efficacy in several Chuvash patients [31]. JAK 
inhibitors may prove to be a useful therapeutic option for those with the congenital erythrocytosis 
of the Chuvash variety in the future. 
Conclusion 
Rare individuals presenting often at a young age and perhaps with a family history may have a 
congenital erythrocytosis. They should be investigated for known primary or secondary causes of 
erythrocytosis by molecular investigations. Aspirin and venesection are the main therapeutic options 
that can be considered although there is little evidence to support therapeutic decisions.  However, 
in the majority of individuals currently no lesion can be identified. 
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Table 1: Causes of congenital erythrocytosis 
Primary erythrocytosis 
EPO receptor mutations 
 
 
Secondary erythrocytosis  
Oxygen sensing pathway defects (PHD2, VHL, HIF2A) 
Bisphosphoglycerate mutase deficiency 
High oxygen affinity haemoglobin 
Methaemoglobinaemia 
Hereditary ATP increase 
 
Table 2 Investigations 
History and examination 
Repeat confirmatory FBP 
Red cell mass 
Erythropoietin Level 
P50-Oxygen dissociation Curve 
Haemoglobin Electrophoresis 
Sequencing for known gene variations 
 
 
 
 
 
 
 
 
 
 
Legends for figures 
Figure 1 Erythropoeitin receptor 
Erythropoietin docks with its receptor and autophosphorylates, JAK dimerises STAT and then signals 
to produce red cells. The receptor is down-modulated by SHP-1. A mutation in the gene leads to a 
truncated receptor which has lost the site of attachment of SHP-1 and therefore cannot be down- 
modulated and continues to signal to produce red cells without more erythropoietin. 
Figure 2 Oxygen sensing pathway 
In normoxia prolyl hydroxylases (PHDs) hydroxylate hypoxia inducible factor (HIF) which binds to 
von-Hippel-Lindau tumour suppressor protein (VHL). Ubiquitination and degradation of HIF then 
occurs in the proteasome. In hypoxic conditions HIF-2a in not degraded but binds to the Beta 
subunit, translocates to the nucleus and causes production of further proteins including 
erythropoietin. 
